Ibogaine Contraindications: Who Should Not Take This Treatment
Ibogaine can kill you. This is not a scare tactic. It is a documented fact across multiple published case reports. Before considering ibogaine for addiction or any other purpose, you need to understand the specific conditions and situations that make this treatment dangerous or potentially fatal.
The medical literature contains detailed accounts of deaths and serious adverse events following ibogaine use. Most of these cases share common patterns. Understanding these patterns could save your life.
Cardiac Conditions and Ibogaine Drug Interactions
The heart is where ibogaine poses its greatest risk. QT prolongation, a measurable change in the heart's electrical activity, appears consistently in case reports of ibogaine toxicity and death.
A case report described a patient who experienced multiple episodes of cardiac arrest during ibogaine treatment for opioid dependence (Mestre et al., 2024). The patient required repeated resuscitation. This occurred in a treatment setting, not from recreational use.
Another documented case involved a patient who developed torsades de pointes, a life-threatening heart rhythm, caused by ibogaine toxicity (Hildyard et al., 2016). Torsades de pointes can rapidly deteriorate into cardiac arrest.
If you have any of the following, ibogaine presents serious cardiac risks:
- Pre-existing QT prolongation or long QT syndrome
- History of arrhythmias or irregular heartbeat
- Heart failure or structural heart disease
- Family history of sudden cardiac death
How does ibogaine interact with other medications? Many common drugs also prolong QT interval. Taking ibogaine while on these medications compounds the cardiac danger. This includes certain antibiotics, antipsychotics, some antidepressants, and methadone. Before any ibogaine treatment, you must know exactly what is in your system. Check potential interactions using our drug interaction checker.
Ibogaine SSRI Interaction Review: Why Antidepressants Matter
Serotonin-affecting medications require special attention. Ibogaine has complex effects on multiple neurotransmitter systems. Combining it with SSRIs, SNRIs, or MAOIs creates unpredictable and potentially dangerous interactions.
A review of ibogaine-associated death noted that understanding the mechanisms and potential risks requires familiarity with how ibogaine affects the body (Meisner et al., 2016). In practice, this means anyone on psychiatric medications needs a carefully managed washout period before ibogaine treatment. The duration depends on the specific medication's half-life.
The part people miss: they stop their antidepressant a few days before treatment thinking they are safe. Some medications take weeks to fully clear the body. Rushing this process creates real danger.
Ibogaine Contraindications: Psychosis and Mental Health History
Ibogaine produces intense psychological experiences. For some individuals, this poses serious psychiatric risks.
A case series documented mania following ibogaine use in multiple patients (Marta et al., 2015). The researchers noted that ibogaine is sought out primarily in poorly regulated overseas clinics, and existing serious adverse events include cardiac complications and now documented psychiatric episodes. This adds another dimension to ibogaine side effects contraindications that many treatment seekers overlook.
You should not take ibogaine if you have:
- History of psychosis or schizophrenia
- Bipolar disorder, especially with prior manic episodes
- Active severe psychiatric conditions
Ibogaine Contraindications: Seizures and Brain Tumor Considerations
Neurological conditions create additional concerns. The published literature does not provide extensive controlled data on ibogaine in people with seizure disorders or brain tumors. However, given ibogaine's effects on brain activity, these conditions represent reasonable exclusion criteria used by treatment providers.
A case series examining an iboga microdosing protocol for brain injury patients reported on individuals with post-concussive and hypoxic brain injury syndromes (Tabaac et al., 2026). This involved a specific microdosing approach in selected patients, not standard flood doses. Applying these findings broadly would be inappropriate. Evidence for ibogaine use in neurological conditions remains extremely limited.
Ibogaine Liver Disease Contraindication Review
The liver processes ibogaine and its metabolites. Compromised liver function affects how your body handles the compound and for how long.
In a fatal case, a 27-year-old male died twelve hours after ingesting powdered iboga root during withdrawal treatment (Mazoyer et al., 2013). Researchers quantified ibogaine and ibogamine in the victim's body fluids. While this case involved multiple factors, liver function determines drug metabolism and clearance.
Another death case involved a man using ibogaine for heroin addiction (Jalal et al., 2013). Long-term opioid users often have compromised organ function. Thorough medical screening before treatment matters.
What the UK Poison Data Shows About Ibogaine Side Effects
A retrospective analysis of telephone inquiries to the United Kingdom National Poisons Information Service over a 10-year period (2012-2022) examined ibogaine toxicity cases (Edwards et al., 2025). The researchers noted that ibogaine is not licensed in the United Kingdom but is used by individuals attempting to address drug or alcohol use. This data shows that toxicity cases reach poison control services with some regularity.
Another documented case from Serbia involved death due to ibogaine consumption (Aćimović et al., 2021). The report described ibogaine's potential to cause stimulant effects, euphoria, and hallucinations depending on dose. At higher doses or in vulnerable individuals, outcomes can be fatal.
When Ibogaine Has Helped: Context Matters
Some published reports describe positive outcomes. A case report documented remission of severe opioid use disorder following ibogaine treatment (Cloutier-Gill et al., 2016). The authors acknowledged that while opioid agonist medications remain the mainstay treatment, some individuals either refuse or fail these standard approaches.
A recent case report described sustained abstinence from severe ketamine use disorder following ibogaine treatment (Pérez Rosal et al., 2026). The patient had a five-year history of severe polysubstance dependence. This represents a single case, not evidence that ibogaine works for everyone with similar conditions.
The difference between positive and tragic outcomes often comes down to proper screening. Deaths have occurred temporally related to ibogaine use even though evidence exists that ibogaine may disturb heart rhythm (Papadodima et al., 2013). Proper cardiac monitoring and patient selection are not optional extras.
Practical Takeaway
If you are considering ibogaine treatment, get comprehensive cardiac screening including an ECG. Disclose every medication you take, including supplements. Be honest about your complete psychiatric history. Check all potential drug interactions using our interaction checker.
Ibogaine is not for everyone. The people who have died following ibogaine use were often seeking help for serious problems. Proper screening exists to prevent you from becoming another case report.